Table 1 HIV patients stable on ART retain elevated humoral and cellular responses to CMV and advanced T-cell senescence

n

20

16

9

Male:Female

19:1

14:2

9:0

Age (years)

62.5 (50–73)^a

60 (50–74)^a

55(52–69)^a

0.19

0.03

0.12

Levels in Plasma

CMV lysate antibody AU/L

94 (23–995)

20 (6–83)

0.8 (0.5–1.1)

<0.0001

<0.0001

<0.0001

CMV gB antibody AU/L

127 (27–400)

45 (2–88)

2 (0.6–3.3)

<0.0001

<0.0001

<0.0001

CMV IE-1 antibody AU/L

49 (8–1098)

9 (2–180)

2.6 (1.9–10)

<0.0001

<0.0001

0.003

sCD14 ng/mL

22 (7.7–48)

18 (8.3–39)

22 (11–31)

0.09

0.23

0.68

sTNFR1 pg/mL

15 (9.1–25)

15 (12–27)

17 (10–21)

0.68

0.83

0.72

Total IgG mg/mL

12 (3–22)

12 (5–20)

9.4 (6.5–15)

0.46

0.16

0.14

sBAFF ng/mL

740 (376–1401)

519 (274–786)

319 (318–471)

0.002

0.0003

0.06

IFNγ spots per 2 × 10⁶ cells

CMV lysate

227 (16–700)

157 (13–617)

0 (0–0.5)

0.16

<0.0001

<0.0001

CMV pp65

445 (14–1591)

138 (18–645)

0 (0–2)

0.005

<0.0001

<0.0001

CEF control peptide pool

516 (2–1500)

337 (20–584)

4 (0–404)

0.07

0.001

0.0015

NLV peptide

498 (56–1363)^c

214 (13–651)^d

na

0.06

na

na

VLE peptide

420 (14–2000)^c

25 (7–561)^d

na

0.005

na

na

T cell subset [as % of]

CD4⁺ T cells [lymphocytes]

43 (24–77)

69 (52–84)

69 (52–80)

<0.0001

0.0009

0.93

CD57⁺ [CD4]

11 (2–75)

8 (2–26)

4.5 (1.7–7.4)

0.11

0.001

0.03

CD57⁺CD45RA⁺CD27⁻ [CD4]

1.9 (0–57)

0.44 (0.06–14)

0.02 (0.005–0.16)

0.06

0.0002

0.0001

CD8⁺ T cells [lymphocytes]

48 (16–71)

22 (7–43)

21 (15–44)

0.0001

0.002

0.97

CD57⁺ [CD8]

47 (17–67)

40 (6.4–69)

28 (10–68)

0.08

0.04

0.51

CD57⁺CD45RA⁺CD27⁻ [CD8]

19 (4.2–53)

26 (4–49)

8 (2–19)

0.61

0.03

0.0001